Reconcile current and considered medications.
THE CLINICAL WORKFLOW
The Same Workflow.
A Smarter, More Informed Outcome.
BluPRINTRx adds a layer of pharmacokinetic intelligence at steps 3, 4 and 5—without changing the workflow. The workflow clinicians already use, with more precise, patient-specific information to help reduce risk and save time.
CURRENT WORKFLOW
Consider patient-specific factors and diagnoses.
Review alerts, prescribing guidance and clinical experience.
Select or adjust medication and dosing.
Monitor response and make further adjustments as needed.
↓
BLUPRINTRx INTELLIGENCE WORKFLOW Same workflow. BluPRINTRx adds a layer of pharmacokinetic intelligence at steps 3, 4 and 5.
Reconcile current and considered medications.
Consider patient-specific factors and diagnoses.
Identify which risks matter most in this patient based on functional pharmacokinetics, DDIs and clinical context.
Support faster, more informed medication decisions with patient-specific, evidence-supported information.
Continuously reassess the medication picture as medications, response and patient factors change.
◷ Save TimeDirectly to what matters most.
◎ More PrecisionPatient-specific risk prioritization.
♢ Lower RiskOngoing monitoring and faster intervention.
HOW BLUPRINTRX FITS INTO THE WORKFLOW
Eight Points of Medication Intelligence
Expand each point to see how patient-specific pharmacokinetic information can support the medication workflow without replacing provider judgment.
01Current Medication Picture+
Bring current and considered medications into one view so the medication regimen is evaluated as a connected system rather than as isolated prescriptions.
02Patient Factors+
Organize relevant patient context—including diagnoses, age, organ function and other available factors—for licensed healthcare providers to evaluate alongside the medication list.
03Pharmacogenomic Starting Point+
When PGx is available, incorporate inherited metabolic information as a starting point. When PGx is not available, BluPRINTRx can still evaluate medication-driven pharmacokinetic factors without representing genetics as tested.
04Functional Pharmacokinetic Intelligence+
TruTYPE® evaluates medication effects on metabolic pathways—including clinically relevant inhibition, induction and phenoconversion—to provide a current functional PK picture.
05Medication Exposure & Interaction Context+
Identify where one or more medications may have increased or decreased exposure and place established drug–drug and pathway interactions into patient-specific PK context.
06Prioritized Medication Risk+
TruRISK™ uses functional PK and medication context to help organize established medication risks so providers can focus attention on the risks that may be most relevant to the patient now.
07Therapy & Dosing Considerations+
TruSELECT™ and PHELIX intelligence can surface evidence-supported therapy, dosing and medication-action information for clinician evaluation while keeping published guidance distinct from Sozos-generated intelligence.
08Monitor, Reassess & Recalculate+
As medications and patient factors change, reassess the functional medication picture so new exposure risks, interactions and therapy considerations can be identified for provider review.